BPG is committed to discovery and dissemination of knowledge
Prospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Jun 27, 2026; 18(6): 118083
Published online Jun 27, 2026. doi: 10.4240/wjgs.118083
Table 1 General characteristics of patients, n (%)/mean ± SD
Group
Observation group
Control group
t/χ2 value
P value
Age (years)56.4 ± 12.357.1 ± 11.80.330.742
Sex0.130.718
    Male41 (63.08)39 (60.00)
    Female24 (36.92)26 (40.00)
Type of ulcer0.120.725
    Gastric ulcer38 (58.46)36 (55.38)
    Duodenal ulcer27 (41.54)29 (44.62)
Forrest classification0.140.705
    Ia-IIb44 (67.69)46 (70.77)
    Other21 (32.31)19 (29.23)
Cardiovascular disease0.150.702
    Yes19 (29.23)21 (32.31)
    No46 (70.77)44 (67.69)
Prior use of antithrombotic medications0.150.699
    Yes16 (24.62)18 (27.69)
    No49 (75.38)47 (72.31)
Table 2 Rebleeding rates after therapeutic endoscopy, n (%)
Group
Seven-day rebleeding
30-day rebleeding
Observation group (n = 65)4 (6.15)6 (9.23)
Control group (n = 65)12 (18.46)16 (24.62)
χ2 value4.565.47
P value0.0330.019
Table 3 Hospital stay and blood transfusion volume, mean ± SD
Group
Inpatient days
Blood transfusion volume (U)
Observation group (n = 65)6.8 ± 2.11.3 ± 0.9
Control group (n = 65)8.1 ± 2.61.9 ± 1.1
T value3.143.40
P value0.002< 0.001
Table 4 Complications and patient satisfaction, n (%)
Group
Complications
Number of satisfied patients
Aspiration
Hypotension
Arrhythmia
Total incidence
Observation group (n = 65)1 (1.54)3 (4.62)2 (3.08)6 (9.23)60 (92.31)
Control group (n = 65)5 (7.69)9 (13.85)7 (10.77)21 (32.31)51 (78.46)
χ2 value---10.024.99
P value---0.0020.025


Write to the Help Desk